Navigation Links
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
Date:8/7/2014

ollaboration agreement with Sanofi Pasteur. KaloBios has stated that it intends to seek a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the future development of KB001-A."We are very excited about the recent progress we have made on our programs," said Nestor A. Molfino, MD, MSc, Chief Medical Officer of KaloBios. "Completing enrollment in our Phase 2 KB001-A study in CF patients in a timeframe that will potentially allow us to report out top-line data in early 2015 was a major achievement for the company. At the same time, completing enrollment in the KB004 Phase 1 dose escalation study sets the stage for us to initiate enrollment in the high-dose cohorts in the Phase 2 efficacy-seeking portion of our KB004 study in the second half of 2014."

Key Anticipated Milestones for 2014-20152H 2014:Full enrollment of the KB001-A CF Phase 2 study (completed in July 2014)Q4 2014:

Completion of enrollment in at least one indication in the Phase 2 expansion portion of our KB004 study in hematologic malignanciesQ1 2015:

Top line KB001-A CF Phase 2 study resultsSecond Quarter 2014 Financial Results
Net loss for the three months ended June 30, 2014 was $9.8 million or $0.30 per common share, as compared to $11.8 million or $0.49 per common share for the same period in 2013. 

No contract revenue was reported for the second quarter of 2014 as compared to $15,000 reported in the same period in 2013. The decrease in contract revenues was due to the completion of all substantive performance obligations related to research support activities under our agreement with Sanofi Pasteur.

Research and development (R&D) expenses were $6.7 million for the three months ended June 30, 2014 as compared to $9.6 million for the same period in 2013. The decrease in R&D expense was primarily due to decreased clinical trial activity compared with the prior period
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. KaloBios Provides Update on KB001-A Partnership and Clinical Status
2. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
5. KaloBios to Present at Leerink Swann Rare Disease Roundtable
6. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
7. Herb C. Cross to Join KaloBios as Chief Financial Officer
8. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
9. KaloBios to Present at Stifel Healthcare Conference 2013
10. KaloBios Reports First Quarter 2013 Financial Results
11. KaloBios to Present at Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... 2014 PuraMed BioScience®, Inc., (OTC Pink: PMBS), ... and healthcare products, announced it received the initial funding ... advanced headache relief product, for planned distribution to 1,000 ... , Washington State , and ... MigraPure H Advanced headache relief gel formulation completed, PuraMed ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... Mass., Dec. 10 Cequent Pharmaceuticals, a pioneer in ... to prevent and treat human disease, announced that the ... Evaluation and Research (CBER) approved Cequent,s first IND (investigational ... initiate the first-ever trial of an orally administered RNA ...
... , MILFORD, Mass., Dec. ... announced today that it is partnering with the NC ... in Winston-Salem, NC, to educate and train students and ... state,s burgeoning biopharmaceutical industry. The Pharmaceutical Center, which is ...
Cached Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , FRIDAY, July 31 (HealthDay News) -- A gene associated ... blindness, has been identified by scientists. , The EphA2 gene ... of damaged proteins in the eye. Expression of the EphA2 ... together and cause the eye lens to become cloudy, resulting ...
... , , , LAWRENCE, ... ), a leading manufacturer of innovative dialysis products, today announced that ... Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at ... NxStage,s investor presentation is scheduled for Tuesday, August 11th at 10:00 ...
... , , WOODLAND HILLS, Calif., ... provider of advertising and marketing opportunities for national brands in health ... (NYHRC) chain has agreed to join its network. , ... HCMN will immediately begin installation of its static and digital panel ...
... , CHENNAI, India, July 31 ... Children,s Hospital, the,First Standalone Quaternary Care Paediatric Hospital in the ... ) , The Apollo Children,s ... adolescents up to the age of 16 years all,under one ...
... ... section featuring the latest news and trends from the "wellness" world. , ... Seattle, WA (PRWEB) July 31, ... and sleep-deprived society, alternative medicine and natural health have become a great alternative to ...
... ... to disseminating information on dentistry,s role in the recognition and management of snoring and sleep ... the second month in a row. , ... New York, NY (PRWEB) July 31, 2009 -- Snoring Isn,t Sexy, LLC, a ...
Cached Medicine News:Health News:NxStage to Present at the Canaccord Adams Global Growth Conference 2Health News:Health Club Media Network Adds New York Health & Racquet Club 2Health News:Oscar Award Winner, Dr. A.R. Rahman inaugurates Apollo Children's Hospital - the First Standalone Quaternary Care Paediatric Hospital in the Apollo Hospitals Group 2Health News:Natural Healers Launches "Wellness Community Bulletin" 2Health News:Natural Healers Launches "Wellness Community Bulletin" 3Health News:Natural Healers Launches "Wellness Community Bulletin" 4Health News:SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. The procedure can be done in the office under topical anesthesia. Complete Set Includes Vacuum Speculum, ...
... family of temporary sensing and pacing leads. ... in temporary pacing leads and improved upon ... use and less traumatic to heart tissue. ... designed to provide consistent temporary sensing and ...
Carbo-Seal Valsalva AAP is the first valved graft to replicate the natural Sinus of Valsalva, encouraging the natural formation of systolic vortices....
Medicine Products: